When a specific blocker for αVβ3 is used, reduced PANC-1 tumor mass in a mouse xenograft model, increased proapoptotic BcLx-s expression, reduced tumor hemoglobin content (a marker of angiogenesis), and decreased expression of epidermal growth factor receptor (EGFR) could be observed [113]. This evidence concerns the gene BCL2L1 and neoplasm.